HAM Clinical Trial
Official title:
Immunotherapy of Natural Killer in HTLV-1 Associated Myelopathy
HTLV-1 Associated Myelopathy is a chronic disease of the spinal cord, caused by a virus called human T lymphotropic virus type 1（HTLV−1）. Natural Killer cells provide rapid responses to viral-infected cells, acting at around 3 days after infection, and respond to tumor formation. In this trial, the investigators aim to study the therapeutic safety and the effect on HTLV-1 virus. This in turn will improve the knowledge and understanding of the disease and should lead to better therapy.
HAM is a chronic disease of the spinal cord, caused by a virus called HTLV−I. Natural Killer
cells provide rapid responses to viral-infected cells, acting at around 3 days after
infection, and respond to tumor formation. In this trial, the investigators aim to study the
therapeutic safety and the effect on HTLV-1 virus. This in turn will improve the knowledge
and understanding of the disease and should lead to better therapy.
In a single-center, one year open-label trial, 5 HAM patients will be treated with single
intravenous injection of NK cells (0.9~1*10^9). Then, the the clinical effect was evaluated
by dynamic analysis of Osame's Motor Disability Score and other related physiological
indices, such as HTLV-1 antibody titer in blood and cerebrospinal fluid.
;